Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Tiacci

The Braf Inhibitor Vemurafenib Plus Rituximab Produces a High Rate of Deep and Durable Responses in Relapsed/Refractory Hairy Cell Leukemia: Updated Results of a Phase-2 Trial

Hematological Oncology

English

Ebv Leaves Its Mark: New Evidence of > Hypothesis in B-Cell Lymphomas From Non-Conventional Methods

Hematological Oncology

English

Related publications

Rapid and Durable Responses With the Syk/Jak Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination With Rituximab

Hematological Oncology

English

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Hematological Oncology

English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

English

Five Years of Experience With Rituximab Plus High-Dose Dexamethasone for Relapsed/Refractory Chronic Lymphocytic Leukemia

Archives of Medical Science

Medicine

2016

English

Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)

Leukemia and Lymphoma

English

Phase I Trial of SAR103168, a Novel Multi-Kinase Inhibitor, in Patients With Refractory/Relapsed Acute Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma

English

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-Cvad Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Journal of Clinical Oncology

English

Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial

Hematological Oncology

English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Tiacci

The Braf Inhibitor Vemurafenib Plus Rituximab Produces a High Rate of Deep and Durable Responses in Relapsed/Refractory Hairy Cell Leukemia: Updated Results of a Phase-2 Trial

Ebv Leaves Its Mark: New Evidence of > Hypothesis in B-Cell Lymphomas From Non-Conventional Methods

Related publications

Rapid and Durable Responses With the Syk/Jak Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination With Rituximab

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Five Years of Experience With Rituximab Plus High-Dose Dexamethasone for Relapsed/Refractory Chronic Lymphocytic Leukemia

Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)

Phase I Trial of SAR103168, a Novel Multi-Kinase Inhibitor, in Patients With Refractory/Relapsed Acute Leukemia or High-Risk Myelodysplastic Syndrome

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-Cvad Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma